Ambeed.cn

首页 / 抑制剂/激动剂 / 抗感染 / Antibacterial / Levofloxacin hydrate/左氧氟沙星半水合物

Levofloxacin hydrate/左氧氟沙星半水合物 {[allProObj[0].p_purity_real_show]}

货号:A126121 同义名: 左氧氟沙星半水合物 / Levofloxacin hemihydrate; Levaquin hydrate

Levofloxacin hydrate是一种抗生素,针对革兰氏阴性菌,通过抑制细菌 DNA 回旋酶的超螺旋活性来阻止 DNA 复制。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Levofloxacin hydrate/左氧氟沙星半水合物 化学结构 CAS号:138199-71-0
Levofloxacin hydrate/左氧氟沙星半水合物 化学结构
CAS号:138199-71-0
Levofloxacin hydrate/左氧氟沙星半水合物 3D分子结构
CAS号:138199-71-0
Levofloxacin hydrate/左氧氟沙星半水合物 化学结构 CAS号:138199-71-0
Levofloxacin hydrate/左氧氟沙星半水合物 3D分子结构 CAS号:138199-71-0
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Levofloxacin hydrate/左氧氟沙星半水合物 纯度/质量文件 产品仅供科研

货号:A126121 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Levofloxacin hydrate/左氧氟沙星半水合物 生物活性

靶点
  • Topo II

描述 Levofloxacin (Hemihydrate) is a fluoroquinolone antibiotic and is the optical S-(-) isomer of the racemic drug substance ofloxacin. It has a broad spectrum of in vitro activity against Gram-positive and Gram-negative bacteria, as well as certain other pathogens such as Mycoplasma, Chlamydia, Legionella and Mycobacteria spp. Plasma concentrations in healthy volunteers reach a mean peak drug plasma concentration (Cmax) of approximately 2.8 and 5.2 mg/L within 1 to 2 hours after oral administration of levofloxacin 250 and 500 mg tablets, respectively[3]. In stable COPD (chronic obstructive pulmonary disease), levofloxacin treatment causes a short-term reduction in bacterial load[4]. Levofloxacin was found to significantly improve the clinical and microbiological parameters in CP (chronic periodontitis) individuals[5]. A 30-day course of levofloxacin does not significantly improve BK viral load reduction or allograft function when used in addition to overall reduction of immunosuppression[6].

Levofloxacin hydrate/左氧氟沙星半水合物 细胞实验

Cell Line
Concentration Treated Time Description References
ZF4 cells 1 × 10^6 CFU/ml 3 hours To test the effect of Lev-S and Lev-R V. alginolyticus on promoter activity in ZF4 cells Microb Biotechnol. 2020 Jul;13(4):1213-1227.
Mycobacterium tuberculosis H37Ra (extracellular) 0.125 mg/L (1xMIC) 7 days To evaluate the bactericidal effect of levofloxacin against extracellular Mycobacterium tuberculosis. Results showed maximal kill (Emax) >7 log10 CFU/mL. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302.
THP-1 cells 0.125 mg/L (1xMIC) 7 days To evaluate the bactericidal effect of levofloxacin against intracellular Mycobacterium tuberculosis. Results showed that the killing effect was 2 log10 CFU/mL lower than against extracellular bacilli. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302.
Elizabethkingia anophelis 0.5 to 128 mg/L 72 hours To determine the minimum inhibitory concentration (MIC) and mutant prevention concentration (MPC) of levofloxacin against Elizabethkingia anophelis and investigate its resistance mechanisms Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0030122.
Stenotrophomonas maltophilia K M6 LEVr 8 μg/ml Determine the MIC of K M6 LEVr against Levofloxacin Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01284-20.
Stenotrophomonas maltophilia K M7 8 μg/ml Determine the MIC of K M7 against Levofloxacin Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01284-20.
Stenotrophomonas maltophilia K M6 4 µg/ml Determine the MIC of K M6 against Levofloxacin Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01284-20.
Stenotrophomonas maltophilia K279a 2 µg/ml Determine the MIC of K279a against Levofloxacin Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01284-20.

Levofloxacin hydrate/左氧氟沙星半水合物 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Zebrafish (Danio rerio) Zebrafish infection model Intramuscular injection 9 × 10^5 CFU/fish Single injection, observed for 6 days To evaluate the differences in pathogenicity and immunogenicity between Lev-R and Lev-S V. alginolyticus in zebrafish Microb Biotechnol. 2020 Jul;13(4):1213-1227.

Levofloxacin hydrate/左氧氟沙星半水合物 参考文献

[1]Mourelle-Insua A, Lopez-Iglesias M, et al.Stereoselective Access to 1-[2-Bromo(het)aryloxy] propan-2-amines Using Transaminases and Lipases; Development of a Chemoenzymatic Strategy Toward a Levofloxacin Precursor. J Org Chem. 2016 Oct 21;81(20):9765-9774.

[2]Mori K, Maru C, Takasuna K. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro. J Pharm Pharmacol. 2000 May;52(5):577-84.

[3]Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet. 1997;32(2):101–119

[4]Siva R, Bafadhel M, Monteiro W, Brightling CE, Pavord ID. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2014;9:179–186.

[5]Pradeep AR, Singh SP, Martande SS, et al. Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent. 2015;6(3):170–178

[6]Lee BT, Gabardi S, Grafals M, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014;9(3):583–589

Levofloxacin hydrate/左氧氟沙星半水合物 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.35mL

0.27mL

0.14mL

6.75mL

1.35mL

0.68mL

13.50mL

2.70mL

1.35mL

Levofloxacin hydrate/左氧氟沙星半水合物 技术信息

CAS号138199-71-0
分子式C36H42F2N6O9
分子量 740.75
SMILES Code O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.[H]O[H].O=C(C(C5=O)=CN6[C@@H](C)COC7=C(N8CCN(C)CC8)C(F)=CC5=C67)O
MDL No. MFCD07772024
别名 左氧氟沙星半水合物 ;Levofloxacin hemihydrate; Levaquin hydrate; Cravit hydrate; Iquix hydrate; Quixin hydrate; Tavanic hydrate
运输蓝冰
InChI Key SUIQUYDRLGGZOL-RCWTXCDDSA-N
Pubchem ID 3033924
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, room temperature

溶解方案

DMSO: 7 mg/mL(9.45 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 50 mg/mL(67.5 mM)

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。